Disclosure Dr. Kim reports receiving institutional funding from Roche-Genentech, LoxoLilly, Mirati-BMS, BridgeBio, Genmab, Bioinvent, AstraZeneca, MonteRosa, Boehringer-Ingelheim, Dynamicure, Seagen, Gilead, Takeda, Vaccibody, Alentis, Abbvie, and advisory board fees from Revolution Medicine, Boehringer-Ingelheim, and Amgen outside the present work. Dr. Politi reports receiving institutional funding from AstraZeneca, Roche-Genentech, D2G Oncology, and Boehringer Ingelheim, consulting and advisory fees from Revelio Therapeutics, Pfizer, AstraZeneca, and Johnson&Johnson, and travel fees from Roche-Genentech; has received royalties from licensing of a patent for T790M testing to MolecularMD by MSKCC; and is a cofounder of and holds stock in Revelio Therapeutics. Dr. Goldberg reports receiving institutional funding from AstraZeneca, Boehringer Ingelheim, Mirati, Adela, Johnson&Johnson, ORIC pharmaceutics, Roche-Genentech, Daiichi-Sankyo, Agenus, Genentech, Amgen, Merck, Vitrac, and Spectrum; and received advisory board fees from AstraZeneca, Eli Lilly, Daiichi-Sankyo, Johnson&Johnson, Summit Therapeutics, Merck, Regeneron, Bayer, Synthekine, and Tubulis, outside the present work.